<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639781</url>
  </required_header>
  <id_info>
    <org_study_id>AGE-111-CH</org_study_id>
    <secondary_id>FLA-111-CH</secondary_id>
    <nct_id>NCT01639781</nct_id>
  </id_info>
  <brief_title>Age-dependent Effects of Flavanols on Vascular Status</brief_title>
  <official_title>Age-dependent Effects of Flavanol Metabolism and Absorption on Vascular Status After Acute and Chronic Application.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Reading</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidemiological studies suggest that certain foods rich in flavanols, including cocoa
      products, red wine, and tea, are associated with decreased cardiovascular mortality and
      morbidity. Dietary interventional studies have corroborated this finding and showed that
      flavanols can acutely and after sustained ingestion improve surrogate markers of
      cardiovascular risk including endothelial function. Endothelial dysfunction is the key event
      in the development and progression of cardiovascular disease. Aging is the major
      non-modifiable cardiovascular risk factor associated with progressive decline in endothelial
      function, vascular stiffening and increase in blood pressure. We hypothesize that flavanols
      can counteract age-dependent vascular changes by interacting with key mechanisms, most
      prominently endothelial function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>change in flow mediated dilatation between first treatment at day 0 and after last treatment at day 14</time_frame>
    <description>Flow mediated dilatation (FMD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma flavanol metabolites</measure>
    <time_frame>analysis of metabolites between first treatment at day 0 and after last treatment at day 14</time_frame>
    <description>Measured by HPLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure</measure>
    <time_frame>blood pressure at day 0 and at day 14</time_frame>
    <description>automatical measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>14 days</time_frame>
    <description>Measured by SphygmoCor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular function</measure>
    <time_frame>14 days</time_frame>
    <description>Measured by Laserdoppler perfusion imaging (LDPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation index</measure>
    <time_frame>14 days</time_frame>
    <description>Measured by SphygmoCor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>14 days</time_frame>
    <description>Measured by ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte deformability</measure>
    <time_frame>14 days</time_frame>
    <description>Measured by Laser-assisted Optical Rotation Cell Analyzer (LORCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NO bioavailability</measure>
    <time_frame>14 days</time_frame>
    <description>Measured by CLD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>flavanol rich intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>flavanol rich drink</description>
  </arm_group>
  <arm_group>
    <arm_group_label>flavanol free intervention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>flavanol free drink</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flavanol rich intervention</intervention_name>
    <description>Flavanol intervention drinks contain (400 mg flavanols) flavanol rich drink 2 x 400 mg 2 times a day over 2 weeks</description>
    <arm_group_label>flavanol rich intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flavanol free control</intervention_name>
    <description>Calorically, micro- and macronutrient matched control drink free of flavanols flavanol free drink 2 times a day over 2 weeks</description>
    <arm_group_label>flavanol free intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male participants between 18-35 years

          -  healthy male participants between 50-80 years

        Exclusion Criteria:

          -  acute inflammation

          -  cardiac arrhythmia

          -  renal failure

          -  heart failure (NYHA II-IV)

          -  diabetes mellitus

          -  CRP &gt; 1 mg/dl

          -  malignant disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Heiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Cardiology, Pulmonology and Vascular Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malte Kelm, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Cardiology, Pulmonology and Vascular Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Pulmonology and Vascular Medicine</name>
      <address>
        <city>Duesseldorf</city>
        <state>NRW</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <last_update_submitted>December 14, 2014</last_update_submitted>
  <last_update_submitted_qc>December 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_title>
  </responsible_party>
  <keyword>flavanols</keyword>
  <keyword>age related cardiovascular effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

